Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Poly-Refractory Rheumatoid Arthritis: An Uncommon Subset of a Difficult-to-Treat Disease

  |  

For complete details, including source material, refer to the full study.   

Excerpted and adapted from:

David P, Di Matteo A, Hen O, et al. Poly-refractory rheumatoid arthritis: An uncommon subset of difficult to treat disease with distinct inflammatory and non-inflammatory phenotypes. Arthritis Rheumatol. 2024 Apr;76(4)

ADVERTISEMENT
SCROLL TO CONTINUE

Related Articles

    Common Characteristics in RA Patients Who Don’t Respond to Biologics

    At least 6% of patients who used biologic disease-modifying anti-rheumatic drugs (bDMARDs) suffered refractory disease, according to a recent study based on data from the British Society for Rheumatology Biologics Registry for Rheumatoid Arthritis.1 This observational study evaluated the extent of biologic refractory rheumatoid arthritis (RA). The study defined biologic refractory disease as occurring in…

    A Novel Study Compared the Effectiveness of Adalimumab with Tofacitinib in RA

    Your patient with rheumatoid arthritis (RA) isn’t responding well enough to methotrexate, and you both agree it’s time to consider a biologic or targeted synthetic disease-modifying anti-rheumatic drug (DMARD). But which one should you choose? ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEIn a treat-to-target era, we’re fortunate to have a variety of RA therapies at our disposal….